In a significant ruling, the Delhi High Court addressed key issues in pharmaceutical patent law, particularly concerning coverage disclosure and therapeutic efficacy under Section 3(d) in the Intra Cellular Therapies v. Controller of Patents case.
Delhi High Court Revisits Pharmaceutical Patent Law in Intra Cellular Therapies Case
The Delhi High Court, in its judgment in the case of Intra Cellular Therapies v. Controller of Patents, has examined two pivotal aspects of pharmaceutical patent law: the coverage disclosure distinction in genus-species claims and the therapeutic efficacy threshold defined under Section 3(d) of the Patents Act. The Court's findings highlight the complexities involved in the analysis of patentability regarding pharmaceutical inventions.
Specifically, the judges emphasized that while the Section 3(d) analysis was applied correctly to some extent, several aspects, such as the treatment of coverage as disclosure and the failure to engage with the novelty standard adequately, raise critical concerns. The Court’s silence on the inventive step in this context also adds another layer of complexity to the interpretation of patent law.
This ruling is expected to have significant implications for patent applicants, particularly in the pharmaceutical sector, as it may influence future submissions and discussions surrounding patent disclosure requirements and the assessment of therapeutic efficacy. Practitioners must adjust their strategies in light of this evolving legal landscape, ensuring thorough and compliant patent applications.
Citations
- Intra Cellular Therapies v. Controller of Patents (2026)
